433 related articles for article (PubMed ID: 37238995)
1. Redox Signaling Modulates Activity of Immune Checkpoint Inhibitors in Cancer Patients.
Allegra A; Murdaca G; Mirabile G; Gangemi S
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238995
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations.
Augustin RC; Delgoffe GM; Najjar YG
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348579
[TBL] [Abstract][Full Text] [Related]
3. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
Li K; Tian H
J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
[TBL] [Abstract][Full Text] [Related]
4. Anticancer natural products targeting immune checkpoint protein network.
Chun KS; Kim DH; Raut PK; Surh YJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
6. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
Kok VC
Front Oncol; 2020; 10():268. PubMed ID: 32185135
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
Moehler M; Delic M; Goepfert K; Aust D; Grabsch HI; Halama N; Heinrich B; Julie C; Lordick F; Lutz MP; Mauer M; Alsina Maqueda M; Schild H; Schimanski CC; Wagner AD; Roth A; Ducreux M
Eur J Cancer; 2016 May; 59():160-170. PubMed ID: 27039171
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.
Lecis D; Sangaletti S; Colombo MP; Chiodoni C
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31060225
[TBL] [Abstract][Full Text] [Related]
9. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
10. Tumour-intrinsic resistance to immune checkpoint blockade.
Kalbasi A; Ribas A
Nat Rev Immunol; 2020 Jan; 20(1):25-39. PubMed ID: 31570880
[TBL] [Abstract][Full Text] [Related]
11. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.
Marei HE; Hasan A; Pozzoli G; Cenciarelli C
Cancer Cell Int; 2023 Apr; 23(1):64. PubMed ID: 37038154
[TBL] [Abstract][Full Text] [Related]
14. Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions.
Zhang C; Zhang C; Wang H
Cancer Lett; 2023 May; 562():216182. PubMed ID: 37076040
[TBL] [Abstract][Full Text] [Related]
15. Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy.
Zhang W; Kong X; Ai B; Wang Z; Wang X; Wang N; Zheng S; Fang Y; Wang J
Front Oncol; 2021; 11():582664. PubMed ID: 34631507
[TBL] [Abstract][Full Text] [Related]
16. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
[TBL] [Abstract][Full Text] [Related]
17. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
Hays E; Bonavida B
Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
[TBL] [Abstract][Full Text] [Related]
18. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]